Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Leucine enkephalin - Virpax Pharmaceuticals

Next Previous
Drug Profile

Leucine enkephalin - Virpax Pharmaceuticals

Alternative Names: Envelta™; Leucine enkephalin intranasal spray - Virpax Pharmaceuticals; METDoloron; Nanoenabled leucine5 enkephalin; NES-100; NM 0127; NM 127; PES200

Latest Information Update: 20 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Nanomerics
  • Developer Nanomerics; National Center for Advancing Translational Sciences; University of Exeter; Virpax Pharmaceuticals
  • Class Anxiolytics; Enkephalins; Essential amino acids; Opioid analgesics; Opioid peptides
  • Mechanism of Action Opioid delta receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Pain

Highest Development Phases

  • Preclinical Cancer pain; Pain; Post-traumatic stress disorders
  • No development reported Neuropathic pain

Most Recent Events

  • 15 Nov 2023 Virpax Pharmaceuticals plans a phase-I trial in middle of 2024
  • 18 Sep 2023 PES200 is still in preclinical trials for Post-traumatic stress disorders in Germany (Intranasal)
  • 13 Jul 2023 Virpax files a provisional patent application with the USPTO related to its Envelta product candidate
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top